Linno completed Pre-A fundraising, focusing on enabling technology of blood-brain barrier penetration and the next-generation pathway-selective complement inhibitors
2022-07-18
Linno Pharmaceuticals Inc. (Linno) today announced the completion of the Pre-A fundraising led by Puhua Capital and ZJ LEADING VC.
This round of fundraising will be primarily invested to further develop Linno’s proprietary enabling technology for blood-brain barrier penetration and associated drug development, as well as the next-generation pathway-selective complement inhibitor. Accumulatively, Linno has raised nearly 100 million Chinese Yuan for their programs.